More on FULC

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+100.0% Growth)
- Ratings (6.4 Score)

Upcoming Events

- Earnings (7/29/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Fulcrum Therapeutics Inc. (NQ:FULC)
Delayed: 8.17 +0.01 (0.12%)
Prev. Close $8.16  
Open$8.04 
52 Wk High$ 
52 Wk Low$ 
Day High$8.45 
Day Low$7.95 
P/E N/A  
EPS$ 
Volume773,095 


Mar 6, 2026 04:30 PM Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 3, 2026 08:30 AM Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Feb 25, 2026 09:43 AM Fulcrum Therapeutics (FULC) PT Lowered to $17 at Truist Securities
Feb 24, 2026 02:23 PM Goldman Sachs Reiterates Early-Stage Biotech Rating on Fulcrum Therapeutics (FULC)
Feb 24, 2026 01:12 PM Leerink Partners Reiterates Outperform Rating on Fulcrum Therapeutics (FULC)
Feb 24, 2026 12:50 PM BofA Securities Reiterates Underperform Rating on Fulcrum Therapeutics (FULC)
Feb 24, 2026 10:23 AM Stifel on Fulcrum Therapeutics (FULC): 'we think overly nitpicking 19.3% is splitting hairs and misses the bigger picture'
Feb 24, 2026 10:21 AM Oppenheimer: 'We think FULC shares are trading down today because of profit-taking'
Feb 24, 2026 07:16 AM Form S-8 Fulcrum Therapeutics,
Feb 24, 2026 07:11 AM Form 10-K Fulcrum Therapeutics, For: Dec 31
View All Articles

Entities mentioned with FULC

View All Entities